Lumos Pharma

Focus: Lumos Pharma is a rare disease and oncology-focused pharmaceutical company headquartered in Austin, Texas, with a diversified pipeline spanning immunotherapy, small molecules, and cell-based approaches.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Lumos Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Lumos Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

POC SARS-Cov-2 IgG Antibody test

SARS-Cov-2, Covid19

N/A

Clinical Trials (1)

NCT04699903Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood

N/A

Help build intelligence for Lumos Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Robust pipeline with 20 active trials across multiple modalities, including 2 Phase 3 programs (LUM-201 for GHD and HyperAcute-Pancreatic Cancer Vaccine) offering near-term value inflection catalysts
Focused therapeutic strategy in rare diseases and oncology with clear unmet medical need, providing meaningful impact potential in high-impact areas
Austin headquarters location offers tech-industry talent crossover and cost-of-living advantages versus coastal biotech hubs

Watch Out For

Zero current open positions (activeJobCount: 0) signals organizational stability concerns or potential hiring freeze, limiting immediate career advancement opportunities
Complete absence of financial transparency (no revenue, funding, or R&D spend data) makes it impossible to assess cash runway, financial health, or compensation competitiveness

Generated by Claude from Lumos Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas)

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT03165188Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

N/A

CoviDx™ Covid-19 Antigen Self-Test

SARS-CoV-2

N/A

Clinical Trials (1)

NCT05403346Clinical Evaluation of a COVID-19 Antigen Self-Test (CoviDx™)

N/A

POC CoviDx™ Rapid Antigen Test

SARS-CoV-2

N/A

Clinical Trials (1)

NCT04750629Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)

N/A

Lumos Glasses

Depression

N/A

Clinical Trials (1)

NCT07168954Smart Light Therapy Glasses for Sleep and Mental Wellness

N/A

Training

Chronic Pain

N/A

Clinical Trials (1)

NCT03398408Cognitive Flexibility Training in Persistent Pain

N/A

Bariatric Surgery

Obesity

N/A

Clinical Trials (1)

NCT02994186Examination of Cognitive Function in Obesity and Following Weight Loss

N/A

Lumosity

Multiple Sclerosis (MS)

N/A

Clinical Trials (1)

NCT02612935An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis

N/A

ADHD Therapy

ADHD

N/A

Clinical Trials (1)

NCT05805176An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms

N/A

Breast Cancer Survivorship & Work-Related Cognitive Limitation

Breast Cancer

N/A

ADHD Therapy

ADHD

N/A

Clinical Trials (1)

NCT05296473Guided ADHD Therapy for Managing the Extent and Severity of Symptoms

N/A

FebriDx

Acute Respiratory Infections (ARIs)

N/A

Clinical Trials (1)

NCT07211997FebriDx® Pediatric Validation Study

N/A

Lumosity Cognitive Training

Cognitive Abilities

N/A

Clinical Trials (1)

NCT02367898Enhancing Cognitive Abilities With Comprehensive Training

N/A

RPS InflammaDry Detector™

Dry Eye

N/A

Clinical Trials (1)

NCT01313351RPS InflammaDry Detector™ to Determine MMP-9 Levels in Tears

N/A

FebriDx

Acute Respiratory Tract Infections

N/A

Clinical Trials (1)

NCT02018198FebriDx DISRUPT Acute Respiratory Infection Trial in Acute Respiratory Infection: An Evaluation of FebriDx® POC Test

N/A

Brain Performance Test

Healthy Volunteers

N/A

Clinical Trials (1)

NCT02382393Reliability and Validity of Online Cognitive Assessments

N/A

BPT, Computerized Assessment

Healthy Volunteers

N/A

Clinical Trials (1)

NCT02403609An Online Study of the Reliability of the Brain Performance Test (BPT)

N/A

BPT

Healthy Volunteers

N/A

Clinical Trials (1)

NCT02518204Validity of an Online Neurocognitive Test Battery, the Brain Performance Test (BPT), in Normal Healthy Adults

N/A

Lumosity

Ruptured Aneurysm

N/A

Clinical Trials (1)

NCT02864940Memory Training in Aneurysmal Subarachnoid Hemorrhage Patients

N/A

Rapid point of care test to detect host immune response in ARI

Acute Respiratory Infections (ARIs)

N/A

Clinical Trials (1)

NCT06746259FebriDx® Method Comparison Study Protocol

N/A

RPS Adeno Detector IV

Conjunctivitis

N/A

Clinical Trials (1)

NCT00921895A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis

N/A

PheCheck™

Phenylketonurias

N/A

Clinical Trials (1)

NCT05998109PheCheck Feasibility Study

N/A

An Observational Study of Lumosity in Seniors

Healthy Volunteers

N/A

Clinical Trials (1)

NCT02614755An Observational Study of Lumosity in Seniors

N/A

TMS and Lumosity®cognitive retraining

Cognitive Impairment

N/A

Clinical Trials (1)

NCT03701932Mental Activity During (TMS) Therapy for Depression

N/A

Lumosity

Delirium

N/A

Clinical Trials (1)

NCT02908464Prevention of Early Postoperative Decline

N/A

Digital Program 1

Cognition

N/A

Clinical Trials (1)

NCT05912556Brain Response to an Intervention Using Guided, At-Home Technology for the Mind

N/A

Task Atlas: Study to Develop a Task Atlas of Brain Recruitment During a Digital Game-based Program

Healthy Adults

N/A

Clinical Trials (1)

NCT06376175Task Atlas: Study to Develop a Task Atlas of Brain Recruitment During a Digital Game-based Program

N/A

Foster Care

Socioemotional Development

N/A

Clinical Trials (1)

NCT04165746Early Institutionalization Intervention Impact Project

N/A

Indoximod HCL

Healthy

Phase 1

Clinical Trials (1)

NCT03852446Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers

Phase 1

Indoximod

Glioblastoma Multiforme

Phase 1

Clinical Trials (1)

NCT02502708Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Phase 1

Indoximod base formulation

Healthy

Phase 1

Clinical Trials (1)

NCT03372239Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers

Phase 1

Stereotactic Body Radiotherapy

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT05469490Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors

Phase 1

HyperAcute®-Renal

Metastatic Renal Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT02035358Immunotherapy Study for Metastatic Renal Cell Cancer

Phase 1

Idarubicin

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT02835729A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1

1-methyl-D-tryptophan

Breast Cancer

Phase 1

Clinical Trials (1)

NCT00739609IDO Inhibitor Study for Relapsed or Refractory Solid Tumors

Phase 1

NLG802

Solid Tumor

Phase 1

Clinical Trials (1)

NCT03164603NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Phase 1

CRLX101

Solid Tumors

Phase 1

Clinical Trials (1)

NCT02648711Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Phase 1

Docetaxel

Non-small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT02460367Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Phase 1

Drug: Hyperacute Lung Cancer Cell Vaccine

Non-small Cell Carcinoma

Phase 1/2

Clinical Trials (1)

NCT00073398Vaccine Treatment for Advanced Non-Small Cell Lung Cancer

Phase 1/2

HyperAcute - Breast cancer vaccine

Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT00090480Vaccine Treatment for Advanced Breast Cancer

Phase 1/2

Indoximod

Metastatic Melanoma

Phase 1/2

Clinical Trials (1)

NCT02073123Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Phase 1/2

HyperAcute-Prostate Cancer Vaccine

Prostate Cancer

Phase 1/2

Clinical Trials (1)

NCT00105053Vaccine Treatment for Hormone Refractory Prostate Cancer

Phase 1/2

HyperAcute-Pancreatic Cancer Vaccine

Pancreatic Cancer

Phase 1/2

Clinical Trials (1)

NCT00255827Vaccine Treatment for Surgically Resected Pancreatic Cancer

Phase 1/2

Nab-Paclitaxel

Metastatic Pancreatic Adenocarcinoma

Phase 1/2

Clinical Trials (1)

NCT02077881Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Phase 1/2

Indoximod

Glioblastoma Multiforme

Phase 1/2

Clinical Trials (1)

NCT02052648Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Phase 1/2

CRLX301

Advanced Solid Tumor Malignancy

Phase 1/2

Clinical Trials (1)

NCT02380677Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors

Phase 1/2

Camptothecin

Cancer

Phase 1/2

Clinical Trials (1)

NCT00333502Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Phase 1/2

HyperAcute-Melanoma Vaccine

Malignant Melanoma

Phase 1/2

Clinical Trials (1)

NCT00300612Vaccine Treatment for Advanced Malignant Melanoma

Phase 1/2

CRLX101

Ovarian Cancer

Phase 1/2

Clinical Trials (1)

NCT02389985A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1/2

Docetaxel

Metastatic Breast Cancer

Phase 2

Clinical Trials (1)

NCT01792050Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Phase 2